Literature DB >> 8917445

Chemically and conformationally authentic active domain of human tissue inhibitor of metalloproteinases-2 refolded from bacterial inclusion bodies.

R A Williamson1, D Natalia, C K Gee, G Murphy, M D Carr, R B Freedman.   

Abstract

The aggregation of recombinant proteins into inclusion bodies is a major problem for expression in bacterial systems. The inclusion bodies must be solubilized and the denatured protein renatured if an active molecule is to be recovered. We have developed such a procedure for the active N-terminal domain of tissue inhibitor of metalloproteinases-2 [TIMP-2-(1-127)], a small mammalian protein containing three disulfide bonds. Conditions for its renaturation were determined by studying the refolding behaviour of reduced and denatured mammalian-cell-expressed TIMP-(1-127) by intrinsic fluorescence. This strategy allows the development of a refolding protocol before generation of a bacterial expression system, and allows rapid and systematic optimization of each refolding variable by assessing its effect on the rate and extent of the refolding reaction. TIMP-(1-127) was expressed at high levels in Escherichia coli, and refolded from TIMP-2-(1-127) inclusion bodies, by means of the method developed with mammalian-cell-expressed protein, to give a refolding efficiency of 30-40% and a final yield of 11-14 mg purified protein/l culture. The chemical structure and conformation of this material was characterized by electrospray mass spectrometry and two-dimensional 1H-NMR; no significant differences were found between it and the native protein. Mass analysis of uniformly 13C-labeled and 15N-labeled protein was used to help identify a mistranslated TIMP-(1-127) contaminant in the purified refolded sample. This technique provides additional information on the nature of the modification and allows a distinction to be made between those modifications that are cell derived, and those that arise from subsequent handling of the protein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8917445     DOI: 10.1111/j.1432-1033.1996.00476.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

1.  A new protein folding screen: application to the ligand binding domains of a glutamate and kainate receptor and to lysozyme and carbonic anhydrase.

Authors:  N Armstrong; A de Lencastre; E Gouaux
Journal:  Protein Sci       Date:  1999-07       Impact factor: 6.725

2.  Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.

Authors:  Valeria Arkadash; Gal Yosef; Jason Shirian; Itay Cohen; Yuval Horev; Moran Grossman; Irit Sagi; Evette S Radisky; Julia M Shifman; Niv Papo
Journal:  J Biol Chem       Date:  2017-01-13       Impact factor: 5.157

3.  Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.

Authors:  Albert G Remacle; Sergey A Shiryaev; Ilian A Radichev; Dmitri V Rozanov; Boguslaw Stec; Alex Y Strongin
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

4.  Inactivation of N-TIMP-1 by N-terminal acetylation when expressed in bacteria.

Authors:  Steven R Van Doren; Shuo Wei; Guanghua Gao; Beverly B DaGue; Mark O Palmier; Harinath Bahudhanapati; Keith Brew
Journal:  Biopolymers       Date:  2008-11       Impact factor: 2.505

5.  Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP).

Authors:  Joanna R Worley; Philip B Thompkins; Meng H Lee; Mike Hutton; Paul Soloway; Dylan R Edwards; Gillian Murphy; Vera Knäuper
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

6.  Direct expression of active human tissue inhibitors of metalloproteinases by periplasmic secretion in Escherichia coli.

Authors:  Ki Baek Lee; Dong Hyun Nam; Jacob A M Nuhn; Juan Wang; Ian C Schneider; Xin Ge
Journal:  Microb Cell Fact       Date:  2017-04-28       Impact factor: 5.328

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.